Coeptis Therapeutics Holdings, Inc. announced on January 30, 2025, its rebranding to COEPTIS, Inc. This change marks a transformative shift in its business strategy, moving beyond biopharmaceuticals. The rebranding highlights a commitment to expanding into diverse growth opportunities within technology-driven sectors.
The establishment of the new Technology Division is central to this initiative, aiming to enhance operational capabilities and maximize shareholder value. The recent acquisition of the NexGenAI Affiliates Network platform, an AI-powered marketing solution, aligns with COEPTIS's mission to innovate in highly regulated industries. This integration revolutionizes marketing strategies and operational efficiencies.
Dave Mehalick, President and CEO of Coeptis, stated that this strategic move reinforces the company's commitment to innovation and expansion into revenue-generating, cash flow-positive business units. He emphasized positioning COEPTIS as a self-sustaining entity, creating a robust foundation for long-term growth and profitability. The Technology Division is expanding its automation capabilities and developing AI agents to optimize workflows.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.